As most men now know, an elevated PSA blood test is an indicator of possible prostate cancer.  But only 25-35% of men with elevated PSA levels actually have prostate cancer which can only be confirmed with a biopsy. Due to the inaccuracy of current PSA tests as predictors of prostate cancer, thousands of expensive, painful, and needless biopsies are performed on men each year. A new six-gene whole blood RNA transcript-based diagnostic test developed by Source MDx in Boulder, Colo., was shown in a study of 174 men to be an accurate predictor of prostate cancer in 90% of the cases when used with the PSA test. A larger clinical study is being planned to confirm these results. If the clinical study confirms the initial results, it will be a huge advancement in the diagnosis of prostate cancer, which is nearly as common in men as breast cancer in women.